Nkarta Posts Wider Loss In Q2; Provides Clinical Update On NKX019

(RTTNews) - Nkarta, Inc., (NKTX) a clinical-stage biotech company, posted its second quarter financial results, reflecting a wider net loss compared with the prior-year quarter, primarily attributed to higher operating expenses and lower other income. The company has also provided a clinical update on its lead candidate, NKX019. Company Profile

The company develops allogenic off-the-shelf engineered natural killer (NK) cell therapies for autoimmune diseases. Its lead candidate, NKX019, is a CD19-targeted CAR NK cell therapy being developed for B-cell mediated autoimmune diseases, including lupus nephritis, primary membranous nephropathy, systemic sclerosis, inflammatory myopathy and ANCA-associated vasculitis/polyangiitis.

Q2 Financial Highlights

For the quarter, Nkarta recorded a net loss of $40.37 million, or $0.54 per share, wider than the loss of $22.98 million, or $0.31 per share in the prior-year.

The loss expanded due to higher research and development expenses of $29.05 million from previous year quarter.

General and administrative expenditure surged to $14.08 million from $6.41 million in 2025.

Cash Position

As of June 30, 2026, Cash, cash equivalents, restricted cash, and investments amounted to $243.18 million. The company expects the current cash runway to fund operations through 2029.

Clinical Update

Following discussion with the U.S. FDA on outpatient dosing, Nkarta continues enrollment of patients across the Phase 1/2 Ntrust-1 and Ntrust-2 trial evaluating NKX019 in multiple autoimmune diseases.

Patients are receiving 4 billion cells per dose across three doses, for a total of 12 billion cells, across indications in both trials, with initial clinical data from Ntrust-1 and Ntrust-2 expected to be presented at a medical conference in 2026. NKTX has traded between $1.70 and $3.72 over the past 52-week period.

Nkarta shares closed Monday at $2.46, up 2.07%. In the overnight market, the stock is down $0.81% at $2.44.